Product Information

GRALISE ER 300 MG TABLET is a brand product labeled by Almatica Pharma LLC, priced at $10.1783 per EA under NDC 52427080390. Its NADAC has been published 280 times since Apr 14, 2021.

FDA first approved this application on Jan 28, 2011. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for GRALISE ER 300 MG TABLET has been published 280 times since Apr 14, 2021, and over the history we have for it it has risen 14.4%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 93% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.